Is Exact Sciences a Good Healthcare Stock to Buy Now?

Shares of Exact Sciences (NASDAQ: EXAS), the company behind all of those Cologuard advertisements, popped last week after management convinced some investors it had the means to quickly expand beyond colon cancer screening and genetic tumor profiling. Encouraging results from a study with Exact Sciences' new noninvasive pan-cancer screening recently drove shares of the company up about 25% higher overnight. The method could become the standard technique for detecting multiple forms of cancer in their early stages.